TRIM33 loss in multiple myeloma is associated with genomic instability and sensitivity to PARP inhibitors

Roisin M McAvera, Jonathan J Morgan, Ana B Herrero, Ken I Mills, Lisa J Crawford

Research output: Contribution to journalArticlepeer-review

18 Downloads (Pure)


Deletions of chromosome 1p (del(1p)) are a recurrent genomic aberration associated with poor outcome in Multiple myeloma (MM.) TRIM33, an E3 ligase and transcriptional co-repressor, is located within a commonly deleted region at 1p13.2. TRIM33 is reported to play a role in the regulation of mitosis and PARP-dependent DNA damage response (DDR), both of which are important for maintenance of genome stability. Here, we demonstrate that MM patients with loss of TRIM33 exhibit increased chromosomal instability and poor outcome. Through knockdown studies, we show that TRIM33 loss induces a DDR defect, leading to accumulation of DNA double strand breaks (DSBs) and slower DNA repair kinetics, along with reduced efficiency of non-homologous end joining (NHEJ). Furthermore, TRIM33 loss results in dysregulated ubiquitination of ALC1, an important regulator of response to PARP inhibition. We show that TRIM33 knockdown sensitizes MM cells to the PARP inhibitor Olaparib, and this is synergistic with the standard of care therapy bortezomib, even in co-culture with bone marrow stromal cells (BMSCs). These findings suggest that TRIM33 loss contributes to the pathogenesis of high-risk MM and that this may be therapeutically exploited through the use of PARP inhibitors.

Original languageEnglish
Article number8797
Number of pages11
JournalScientific Reports
Publication statusPublished - 16 Apr 2024

Bibliographical note

© 2024. The Author(s).


  • Humans
  • Poly(ADP-ribose) Polymerase Inhibitors/pharmacology
  • DNA Repair
  • Multiple Myeloma/drug therapy
  • DNA Breaks, Double-Stranded
  • Genomic Instability
  • Transcription Factors


Dive into the research topics of 'TRIM33 loss in multiple myeloma is associated with genomic instability and sensitivity to PARP inhibitors'. Together they form a unique fingerprint.

Cite this